Overview

Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation

Status:
Completed

Trial end date:
2015-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this Phase 2 study is to investigate whether intravenous administration of a wild type reovirus (REOLYSIN®) in combination with paclitaxel and carboplatin is effective and safe in the treatment of Non-Small Cell Lung Cancer with KRAS or EGFR activation.

Phase:

Phase 2

Details

Lead Sponsor:

Oncolytics Biotech

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel